Shakeel Shahzad, Mark D P Willcox, Bushra Jamil, Binod Rayamajhee, Muhammad Yasir
These findings indicate diverse susceptibility patterns of A. baumannii to cationic antimicrobials. Within this exploratory strain collection, polymyxin resistance was not associated with reduced susceptibility to disinfectants or most antimicrobial peptides and was instead associated with lower MICs to certain disinfectants. No evidence of cross-resistance between polymyxins and LL-37 was observed under the conditions tested, suggesting that polymyxin resistance does not necessarily confer reduced in vitro susceptibility to this host defense peptide. Given the small number of polymyxin-resistant isolates, these findings should be considered hypothesis-generating and require confirmation in larger collections of genetically characterized strains. Further mechanistic studies are needed to determine the biological basis and generalizability of these observed susceptibility patterns.
BACKGROUND: Carbapenem-resistant Acinetobacter baumannii is a critical priority pathogen of the Acinetobacter calcoaceticus-Acinetobacter baumannii Complex (Acb Complex) characterized by extensive multidrug resistance, leading to increased reliance on last-line polymyxins and widespread use of cationic disinfectants in healthcare settings. However, shared membrane-targeting mechanisms raise concerns regarding potential cross-resistance between disinfectants, polymyxins, and cationic antimicrobial peptides.
METHODS: A diverse panel of clinical A. baumannii isolates from Australia (n = 9), Pakistan (n = 15), and Switzerland (n = 3), and standard strains (n = 3), including polymyxin-resistant laboratory and clinical mutant strains (n = 4), was used. Minimum inhibitory concentrations (MICs) of polymyxin B, colistin, three cationic disinfectants (polyquaternium-1; PQ-1), polyhexamethylene biguanide (PHMB), and chlorhexidine (CHX), and four Antimicrobial peptides (AMPS: LL-37, melimine, Mel4, and lactoferricin) were determined using broth microdilution. Correlations between MICs were assessed using Spearman analysis, and differences between polymyxin-resistant and -susceptible isolates were analyzed statistically.
RESULTS: Most isolates were susceptible to polymyxins. The MIC data confirmed that one mutant strain, A. baumannii 19606 (R), and three clinical isolates displayed high-level polymyxin B and colistin resistance. PQ-1 exhibited the greatest antibacterial activity among disinfectants, while LL-37 showed the lowest and most consistent MICs among AMPs; lactoferricin was largely inactive. Within this exploratory strain collection, polymyxin-resistant isolates exhibited lower MICs to PQ-1 and PHMB, indicating collateral susceptibility. Correlation analysis revealed significant negative correlations between polymyxin susceptibility and disinfectant MICs (colistin-PQ-1 (r = -0.67 and p = 0.0001), colistin-PHMB (r = -0.44 and p = 0.05), and polymyxin B-PHMB (r = -0.48 and p = 0.005), whereas no consistent correlation was observed between polymyxins and AMPs, including LL-37. A moderate positive correlation was identified between colistin and Mel4 activity (r = 0.45 and p = 0.05).
CONCLUSIONS: These findings indicate diverse susceptibility patterns of A. baumannii to cationic antimicrobials. Within this exploratory strain collection, polymyxin resistance was not associated with reduced susceptibility to disinfectants or most antimicrobial peptides and was instead associated with lower MICs to certain disinfectants. No evidence of cross-resistance between polymyxins and LL-37 was observed under the conditions tested, suggesting that polymyxin resistance does not necessarily confer reduced in vitro susceptibility to this host defense peptide. Given the small number of polymyxin-resistant isolates, these findings should be considered hypothesis-generating and require confirmation in larger collections of genetically characterized strains. Further mechanistic studies are needed to determine the biological basis and generalizability of these observed susceptibility patterns.